Boan Biotechnology: Dexultuzumab Injection Boluojiaxin Indications Approved in China for the Treatment of Solid Tumor Bone Metastasis and Multiple Myeloma

Boan Biotechnology announced that the China National Medical Products Administration has approved a supplemental application for the new indication of Boljia for the treatment of solid tumor bone metastasis patients or multiple myeloma patients, in order to delay or reduce the risk of bone-related events. Boljia is a biosimilar of Angawi, developed independently based on our company's global strategic development. The product was first approved for marketing in China in May 2024 for the treatment of giant cell tumor of bone. The company is also accelerating the process of listing Boljia in more countries and regions worldwide.